search
Back to results

Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).

Primary Purpose

Elevated Intracranial Pressure

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
hypertonic saline
Mannitol
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Elevated Intracranial Pressure focused on measuring clinical trial, mannitol, intracranial pressure (ICP), hypertonic saline, cerebral edema, traumatic brain injury (TBI)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • elevated ICP requiring ICP monitoring
  • ICP ≥ 25 mmHg 5 min after ICP bolt or EVD placement

Exclusion Criteria:

  • Requiring decompressive craniotomy or post decompressive craniotomy
  • Hyponatremia (sodium level < 125 mEq/L)
  • Hypernatremia (sodium > 155 mmol/L)
  • Serum osmolality ≤ 250 mOsm/kg
  • Serum osmolality ≥ 320 mOsm/kg
  • Physical exam compatible with brain death
  • Patients on hemodialysis with end-stage renal disease

Sites / Locations

  • Beth Israel Deaconess Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

hypertonic saline

Mannitol

Arm Description

3% hypertonic saline, dosed by ideal patient weight

20% mannitol, dosed by patient's ideal body weight

Outcomes

Primary Outcome Measures

Percent reduction of ICP from baseline

Secondary Outcome Measures

Time from study drug administration completion to ICP < 25 mmHg
Cumulative duration of ICP below 25 mmHg
Cumulative duration of ICP below 25 mmHg
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Cumulative duration of regional oxygen partial pressure (pbtO2) > 20%
Total dose of medications given
Frequency of treatment failure
Treatment failure defined as ICP > 30 mmHg for > 30 minutes
Frequency of rebound intracranial hypertension
Rebound intracranial hypertension defined as ICP > 25 mmHg for more than 10 minutes following ICP stabilization
Frequency of composite Major Adverse Events
acute kidney injury as defined by an increase in creatinine x 2 or GFR decrease > 50% or urine output < 0.5 ml/kg/h for 12 hours, compared to baseline, as per RIFLE criteria hypotensive episodes (SBP < 90 mmHg for more than 10 minutes) hemodynamic instability as measured by decrease of cardiac output by more than 15% within two hours following medication administration pulmonary edema as defined by ELWI I> 10
Difference in inflammatory response
Determined by analysis of cytokine and inflammatory biomarkers.
Difference in average pre-discharge stroke scale score

Full Information

First Posted
April 16, 2010
Last Updated
March 14, 2017
Sponsor
Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01108744
Brief Title
Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).
Official Title
Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Timeline to consent prior to intervention start was unfeasible.
Study Start Date
January 2012 (undefined)
Primary Completion Date
January 2014 (Anticipated)
Study Completion Date
January 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study goal is to compare the management of increased intra-cranial pressure (ICP) using 3% hypertonic saline vs. mannitol (given in same osmolar loads). Primary hypothesis: 1. Hypertonic saline will be non-inferior to mannitol in decreasing elevated ICP. Secondary hypotheses: Hypertonic saline therapy will result with fewer complications than mannitol ICP reduction duration will be longer using hypertonic saline when compared with mannitol
Detailed Description
There is growing evidence in the literature indicating that ICP and Cerebral Perfusion Pressure measurements may not be sufficient in the management of elevated ICP. Based on this evidence, monitoring of partial brain tissue oxygenation has gain acceptance among neurosurgeons and neurointensivists, and has become a standard of care monitor in some centers across the country. There is, however, insufficient information in the literature describing the effects of hyperosmolar medications on regional brain tissue oxygenation. We intend to undertake this non-inferiority, prospective, randomized double-blind study to answer very important clinical questions not yet answered in the literature: Will hypertonic saline therapy, given at equiosmolar load, be non-inferior to mannitol in reducing elevated ICP?

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Elevated Intracranial Pressure
Keywords
clinical trial, mannitol, intracranial pressure (ICP), hypertonic saline, cerebral edema, traumatic brain injury (TBI)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
hypertonic saline
Arm Type
Active Comparator
Arm Description
3% hypertonic saline, dosed by ideal patient weight
Arm Title
Mannitol
Arm Type
Active Comparator
Arm Description
20% mannitol, dosed by patient's ideal body weight
Intervention Type
Drug
Intervention Name(s)
hypertonic saline
Intervention Description
3% hypertonic saline, dosed by ideal patient weight
Intervention Type
Drug
Intervention Name(s)
Mannitol
Other Intervention Name(s)
Osmitrol
Intervention Description
Mannitol 20% intravenous solution, dosed by patient's ideal body weight
Primary Outcome Measure Information:
Title
Percent reduction of ICP from baseline
Time Frame
30 minutes from completion of medication administration
Secondary Outcome Measure Information:
Title
Time from study drug administration completion to ICP < 25 mmHg
Time Frame
First 72 hours
Title
Cumulative duration of ICP below 25 mmHg
Time Frame
First 24 hours
Title
Cumulative duration of ICP below 25 mmHg
Time Frame
First 72 hours
Title
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Time Frame
First 24 hours
Title
Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg
Time Frame
First 72 hours
Title
Cumulative duration of regional oxygen partial pressure (pbtO2) > 20%
Time Frame
two hours following each dose administration during the first 24 hours
Title
Total dose of medications given
Time Frame
First 24 hours; also over 3 days
Title
Frequency of treatment failure
Description
Treatment failure defined as ICP > 30 mmHg for > 30 minutes
Time Frame
First 72 hours
Title
Frequency of rebound intracranial hypertension
Description
Rebound intracranial hypertension defined as ICP > 25 mmHg for more than 10 minutes following ICP stabilization
Time Frame
First 72 hours
Title
Frequency of composite Major Adverse Events
Description
acute kidney injury as defined by an increase in creatinine x 2 or GFR decrease > 50% or urine output < 0.5 ml/kg/h for 12 hours, compared to baseline, as per RIFLE criteria hypotensive episodes (SBP < 90 mmHg for more than 10 minutes) hemodynamic instability as measured by decrease of cardiac output by more than 15% within two hours following medication administration pulmonary edema as defined by ELWI I> 10
Time Frame
3 days
Title
Difference in inflammatory response
Description
Determined by analysis of cytokine and inflammatory biomarkers.
Time Frame
Regular intervals over first 3 days
Title
Difference in average pre-discharge stroke scale score
Time Frame
hospital discharge (or 30 days if not discharged)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years elevated ICP requiring ICP monitoring ICP ≥ 25 mmHg 5 min after ICP bolt or EVD placement Exclusion Criteria: Requiring decompressive craniotomy or post decompressive craniotomy Hyponatremia (sodium level < 125 mEq/L) Hypernatremia (sodium > 155 mmol/L) Serum osmolality ≤ 250 mOsm/kg Serum osmolality ≥ 320 mOsm/kg Physical exam compatible with brain death Patients on hemodialysis with end-stage renal disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Achikam Oren-Grinberg, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
9464749
Citation
Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE. Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma. 1998 Jan;44(1):50-8. doi: 10.1097/00005373-199801000-00004.
Results Reference
background
PubMed Identifier
13687351
Citation
BARRY KG, BERMAN AR. Mannitol infusion. III. The acute effect of the intravenous infusion of mannitol on blood and plasma volumes. N Engl J Med. 1961 May 25;264:1085-8. doi: 10.1056/NEJM196105252642105. No abstract available.
Results Reference
background
PubMed Identifier
17511539
Citation
Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS; Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma. 2007;24 Suppl 1:S14-20. doi: 10.1089/neu.2007.9994. No abstract available. Erratum In: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.
Results Reference
background
PubMed Identifier
10937895
Citation
The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol. J Neurotrauma. 2000 Jun-Jul;17(6-7):521-5. doi: 10.1089/neu.2000.17.521.
Results Reference
background
PubMed Identifier
11062300
Citation
Bereczki D, Liu M, Prado GF, Fekete I. Cochrane report: A systematic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage. Stroke. 2000 Nov;31(11):2719-22. doi: 10.1161/01.str.31.11.2719.
Results Reference
background
PubMed Identifier
9504569
Citation
Qureshi AI, Suarez JI, Bhardwaj A, Mirski M, Schnitzer MS, Hanley DF, Ulatowski JA. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. Crit Care Med. 1998 Mar;26(3):440-6. doi: 10.1097/00003246-199803000-00011.
Results Reference
background
PubMed Identifier
16720165
Citation
Huang SJ, Chang L, Han YY, Lee YC, Tu YK. Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury. Surg Neurol. 2006 Jun;65(6):539-46; discussion 546. doi: 10.1016/j.surneu.2005.11.019.
Results Reference
background

Learn more about this trial

Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).

We'll reach out to this number within 24 hrs